AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 91 min read$RLYB

Rallybio Corp (RLYB): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Rallybio Corp (RLYB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 8, 2026, Rallybio Corporation (Rallybio) announced that Jonathan Lieber, Rallybio’s Chief Financial Officer,

Original reporting
SEC EDGAR 8-K
Published Sep 9, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$RLYB
Neutral
medium confidence
Mentioned
$RLYB
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RLYBNeutralLow
01

Why it matters

The filing provides the first public details on the CFO's transition, which may influence short‑term sentiment but is unlikely to cause a large price move.

02

Market read

Executive compensation change is a modest corporate‑action news item for a micro‑cap; relevance is limited to investors tracking the merger.

03

What to watch

Severance terms and the part‑time arrangement could affect post‑merger integration costs.

Relevance 6/10Novelty 5/10Timing: filed Sep 9 2026

Background

Rallybio Corp filed an SEC Form 8‑K reporting a change in CFO employment status and compensation ahead of its pending merger with Avenzo Therapeutics.

Company-level read

Ticker impact

$RLYBNeutralMedium confidence
Context

CFO Jonathan Lieber will shift to part‑time status, receive a $420,000 base salary and lose his annual bonus eligibility, with severance tied to the pending merger with Avenzo Therapeutics.

Expected impact

Potential modest downside pressure until merger closes, limited upside.

Evidence & confidence

Executive compensation adjustments are material for a micro‑cap but unlikely to move the stock dramatically without additional merger news.

Market effects

Sector

Limited impact on the broader biotech sector; the filing is company‑specific.

Regional

No discernible effect on regional markets.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The CFO transition could be a sign of internal disagreements that may delay the merger.

Key entities

  • company
    Rallybio Corp

    Biotech firm filing the 8‑K.

  • company
    Avenzo Therapeutics, Inc.

    Merger partner.

  • person
    Jonathan Lieber

    Chief Financial Officer of Rallybio.

Read at source← All news

Related articles

OCT 26
$RLYBHigh

Rallybio Declares Estimated $82.7 Million Special Cash Distribution

Rallybio announced an estimated $82.7M special cash distribution, around $13.56 per share, tied to its proposed merger with Avenzo Therapeutics. The final amount may vary and will be paid on November 13, 2026, pending shareholder approval. The record date is expected to be November 5, with the ex-dividend date set for November 6.

tradingview.com1 min
OCT 26
$RLYBHighAI 8/10

The Rallybio Corporation, a Delaware corporation, entered into an Agreement and Plan of Merger and Reorganization with Avenzo Therapeutics, Inc., a Delaware…

Rallybio Corp (RLYB) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on May 31, 2026, the Rallybio Corporation, a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Avenzo Therapeutics, Inc., a Delaware corporation (“Av

SEC EDGAR 8-K2 min
SEP 9
$RLYBLow

Rallybio's Jonathan Lieber to Shift to Part-Time CFO Role

Rallybio's CFO Jonathan Lieber will transition to a part-time role while retaining his duties and authority, effective September 15, 2026. He will receive a base salary of $420,000 but is ineligible for annual bonuses during this period. The company did not disclose reasons or replacement plans.

tradingview.com1 min
JUN 3
$RLYBMedAI 9/10

RallyBio tries again for reverse merger, this time with Avenzo

RallyBio, which abandoned a reverse merger with Candid Therapeutics after the plan dissolved, announced a new reverse merger with Avenzo Therapeutics, according to the deal announced Monday. The combined company will trade on Nasdaq as AVZO, raise $215 million, and is expected to close by year-end. RallyBio has faced layoffs and disappointing results since going public in 2021.

finance.yahoo.com4 min
JUN 2
$TTRXMedAI 8/10

Top Biotech Gainers: TTRX Turns Heads, LIXT Shifts To AI Energy, CNXU Update, QTRX, TRAX On Watch

Turn Therapeutics (TTRX) rose over 20% after interim Phase 2 results for GX-03 in atopic dermatitis, with 92.6% achieving EASI-50 at 4 weeks. Conexeu (CNXU) gained ~19% on preclinical B.R.E.A.S.T. bioprinting progress. Rallybio (RLYB) jumped on plans to acquire Avenzo via a $215M investment. LIXTE (LIXT) surged on an AI energy pivot; Quanterix (QTRX) rose on insider SEC filing.

rttnews.com7 min